PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Some net income increase while TRVN is negative at -3.14%. John Neff would see a short-term edge over the struggling competitor.
7.12%
Some D&A expansion while TRVN is negative at -1.17%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Both cut yoy SBC, with TRVN at -14.09%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-21.66%
Negative yoy working capital usage while TRVN is 170.79%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while TRVN is 100.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
161.21%
Lower 'other working capital' growth vs. TRVN's 612.33%. David Dodd would see fewer unexpected short-term demands on cash.
200.00%
Some yoy increase while TRVN is negative at -11.81%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.87%
Operating cash flow growth below 50% of TRVN's 48.71%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-183.51%
Negative yoy CapEx while TRVN is 97.92%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
Both yoy lines negative, with TRVN at -32.36%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Negative yoy issuance while TRVN is 13.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.